Bastiano Sanna - 01 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2022
Net transactions value
-$389,172
Form type
4
Filing time
03 Feb 2022, 15:26:09 UTC
Previous filing
03 Nov 2021
Next filing
14 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +11,628 +36% $0.000000 44,204 01 Feb 2022 Direct F1
transaction VRTX Common Stock Award $0 +12,314 +28% $0.000000 56,518 01 Feb 2022 Direct F2
transaction VRTX Common Stock Tax liability $128,155 -526 -0.93% $243.64 55,992 01 Feb 2022 Direct
transaction VRTX Common Stock Sale $167,527 -670 -1.2% $250.04 55,322 02 Feb 2022 Direct F3, F4, F5
transaction VRTX Common Stock Sale $35,457 -141 -0.25% $251.47 55,181 02 Feb 2022 Direct F3, F5, F6
transaction VRTX Common Stock Sale $37,707 -149 -0.27% $253.07 55,032 02 Feb 2022 Direct F3, F5, F7
transaction VRTX Common Stock Sale $16,253 -64 -0.12% $253.95 54,968 02 Feb 2022 Direct F3, F5, F8
transaction VRTX Common Stock Sale $4,073 -16 -0.03% $254.54 54,952 02 Feb 2022 Direct F3, F5, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.
F2 Restricted stock unit award that vests in installments beginning on 02/24/2023.
F3 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F4 Open market sales reported on this line occurred at a weighted average price of $250.04 (range $250.00 to $250.97).
F5 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F6 Open market sales reported on this line occurred at a weighted average price of $251.47 (range $251.09 to $251.85).
F7 Open market sales reported on this line occurred at a weighted average price of $253.07 (range $252.44 to $253.42).
F8 Open market sales reported on this line occurred at a weighted average price of $253.95 (range $253.47 to $254.42).
F9 Open market sales reported on this line occurred at a weighted average price of $254.54 (range $254.47 to $254.80).

Remarks:

Exhibit 24 - Power of Attorney